Hyperforin derivatives, the use thereof and formulations containing them

Abstract

The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease.

1. A pharmaceutical composition comprising: hyperforin and adhyperforin derivative of formula (I) 
       
         
           
           
               
               
           
         
       
       in which R is methyl or ethyl, R 2  is hydrogen, a pharmaceutically acceptable inorganic or organic base cation or a straight or branched C 2 -C 5  acyl residue, and in which, alternatively:
 a) R 1  is 3-methyl-but-1-yl and oxo groups are present at the 1- and 10-positions; 
 b) R 1  is 3-methyl-2-buten-1-yl and hydroxy groups are present at the 1- and 10-positions; 
 c) R 1  is 3-methyl-but-1-yl and hydroxy groups are present at the 1- and 10-positions. 
 
     
     
       2. The derivative pharmaceutical composition as claimed in  claim 1  for the preparation of medicaments for use in the treatment of depression and Alzheimer's disease. 
     
     
       3. The derivative pharmaceutical composition as claimed in  claim 1  in which R 2  of the derivative is hydrogen. 
     
     
       4. A pharmaceutical composition comprising: hyperforin and adhyperforin derivative of formula (I) 
       
         
           
           
               
               
           
         
       
       in which R is methyl or ethyl, R 2  is hydrogen, a pharmaceutically acceptable inorganic or organic base cation or a straight or branched C 2 -C 5  acyl residue, and in which, alternatively:
 a) R 1  is 3-methyl-but-1-yl and oxo groups are present at the 1 and 10-positions; 
 b) R 1  is 3-methyl-2-buten-1-yl and hydroxy groups are present at the 1- and 10-positions; 
 c) R 1  is 3-methyl-but-1-yl and hydroxy groups are present at the 1- and 10-positions, 
 in which R 2  is lithium, R 1  is 3-methyl-but-1-yl and oxo groups are present at the 1- and 10-positions. 
 
     
     
       5. The derivative pharmaceutical composition as claimed in  claim 4  in which R of the derivative is methyl. 
     
     
       6. The derivative pharmaceutical composition as claimed in  claim 1  in which R 2  of the derivative is acetyl, R 1  of the derivative is 3-methyl-but-1-yl and oxo groups are present at the 1- and 10-positions. 
     
     
       7. The derivative pharmaceutical composition as claimed in  claim 6  in which R of the derivative is methyl. 
     
     
       8. A compound selected from:
 dodecahydrohyperforin (Ie), dodecahydroadhyperforin (If), 
 acetyloctahydrohyperforin (Ih) and 
 acetyloctahydroadhyperforin (Ii). 
 
     
     
       9. A pharmaceutical composition containing the compound according to  claim 4 . 
     
     
       10. The compound according to  claim 8 , wherein said compound is dodecahydrohyperforin (Ie). 
     
     
       11. The compound according to  claim 8 , wherein said compound is dodecahydroadhyperforin (If). 
     
     
       12. The compound according to  claim 8 , wherein said compound is acetyloctahydrohyperforin (Ih). 
     
     
       13. The compound according to  claim 8 , wherein said compound is acetyloctahydroadhyperforin (Ii). 
     
     
       14. A pharmaceutical composition containing the compound according to  claim 1 .